Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quality-Of-Life, Emotional Well-Being Becoming Highly Utilized PROs In Diabetes Trials

Executive Summary

Industry mostly using the patient-reported outcomes as exploratory endpoints.

You may also be interested in...



FDA Safety Meetings: Outpatient Drugs, Hypoglycemia Getting Limelight

US agency's events could address a touchy subject: how much responsibility does FDA have for preventing adverse events, and how much falls to physicians?

US FDA Getting More Money Up Front Under Cures Bill Revisions

Additional funding would arrive beginning in FY 2017 as House pushes bill to Senate.

The Evolution Of 21st Century Cures Legislation

Final version of Cures legislation combines several aspects of initial House and Senate legislation, and also includes some completely new elements.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel